Comparative Pharmacology
Head-to-head clinical analysis: DROSPIRENONE ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM versus ESTRADIOL AND NORETHINDRONE ACETATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DROSPIRENONE ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM versus ESTRADIOL AND NORETHINDRONE ACETATE.
DROSPIRENONE, ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM vs ESTRADIOL AND NORETHINDRONE ACETATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of drospirenone (a progestin with antimineralocorticoid and antiandrogenic activity), ethinyl estradiol (an estrogen), and levomefolate calcium (a folate supplement). Prevents ovulation by suppressing gonadotropins; increases cervical mucus viscosity, inhibiting sperm penetration; levomefolate provides folate to reduce neural tube defect risk.
Estradiol is an estrogen that binds to estrogen receptors (ERα/ERβ) to regulate gene transcription involved in reproductive and non-reproductive tissues. Norethindrone acetate is a progestin that binds to progesterone receptors, inducing secretory endometrium and inhibiting gonadotropin secretion.
One tablet orally once daily for 28 days (21 active tablets containing drospirenone 3 mg, ethinyl estradiol 0.02 mg, and levomefolate calcium 0.451 mg, followed by 7 placebo tablets containing levomefolate calcium 0.451 mg).
1 tablet (estradiol 1 mg / norethindrone acetate 0.5 mg) orally once daily; adjust dose based on response and tolerability.
None Documented
None Documented
Drospirenone: ~30 hours (steady state achieved after 8 days). Ethinyl estradiol: ~13-17 hours (biphasic, terminal). Levomefolate calcium: ~4-6 hours (folate derivatives have longer retention).
Estradiol: terminal ~12-14 hours; norethindrone acetate: terminal ~8-11 hours. Steady-state reached within 5-7 days.
Drospirenone: ~50% renal (as metabolites), ~40% fecal. Ethinyl estradiol: ~40% renal, ~60% fecal. Levomefolate calcium: ~70% renal (as folate metabolites), ~30% fecal.
Estradiol: primarily renal as metabolites (glucuronide and sulfate conjugates), ~90% in urine, ~10% in feces as bile. Norethindrone: urinary (50-70% as metabolites) and fecal (20-30%).
Category D/X
Category D/X
Progestin + Estrogen
Progestin